SmithKline Beecham Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (1989)
Status: Acquired by GlaxoSmithKline (2000)

Organization Overview

First Clinical Trial
1995
NCT00169858
First Marketed Drug
1989
nizatidine (axid)
First NDA Approval
1991
onabotulinumtoxinA (Botox)
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SB PHARMCO | SmithKlinBeecham Biologicals | Smith Kline Beecham | SMITHKLINE BEECHAM